Technology | January 11, 2010

Novel Stereotactic Radiosurgery Device Treats AMD in Study

IRay System

January 11, 2010 - The first ever masked and sham-controlled study designed to demonstrate the efficacy and safety of investigational stereotactic radiosurgical device for the treatment of wet age-related macular degeneration (AMD) is now underway at seven European sites.

The device delivers radiation dose using the IRay system, a proprietary non-invasive low energy stereotactic X-ray platform that has been in development since early 2007, developed by Oraya Therapeutics, Inc.

The IRay system is an investigational stereotactic radiosurgical device designed specifically to treat diseases of the eye. The single organ focus of Oraya's technology enables precise delivery of low-energy X-rays to treat wet AMD. Designed to maximize patient comfort and precision, the IRay system utilizes a vacuum-coupled contact lens interface, the I-Guide, which holds the eye to maintain stability during treatment, while detecting eye motion. A gating system, which automatically shuts down the device in case of misalignment due to patient movement, is also featured. Because the radiation delivered is low-voltage, comparable to a chest or dental X-ray, the IRay is suitable for use in a typical ophthalmology office setting. The entire patient treatment process requires only a topical anesthetic, and lasts 15 to 20 minutes.

The study, and will include a minimum of 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray (GY).

All patients will have standard of care anti-VEGF drug therapy, and the trial is designed and powered to measure the effect of the radiation adjunct on vision outcomes and on the frequency of anti-VEGF injections. Trial endpoints will be evaluated one year post radiation treatment. Over 60 patients have already been treated in a Phase 1 study of the device, and results from that study led to the design and initiation of this newly announced trial.

Clinical advisor to Oraya and associate professor of ophthalmology at Stanford University, Darius Moshfeghi, M.D., says data from the Phase 1 study showed an excellent safety profile.

Combination therapies as adjuncts to anti-VEGF therapy are showing great promise to improve the overall treatment options and outcomes for wet AMD patients, according Peter Kaiser, M.D., of the Cole Eye Institute at the Cleveland Clinic, who is a renowned expert on new therapies for AMD, and participated in the design of Oraya's European protocol.

For more information: / and (identifier NCT01016873)

Related Content

FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" was presented by Parag P
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
Adding Radiation to Chemotherapy May Dramatically Improve Survival for Advanced-Stage NSCLC Patients
News | Stereotactic Body Radiation Therapy (SBRT) | September 26, 2017
Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC)...
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Surgery and High-Dose SBRT Radiation Can Be Combined to Treat Kidney Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | July 05, 2017
A new study from Roswell Park Cancer Institute reporting the findings of the first clinical trial to evaluate the...
ASTRO Issues Guideline for Stereotactic Radiation Use in Early-Stage Lung Cancer
Feature | Lung Cancer | June 23, 2017
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical guideline for the use of...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Overlay Init